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Management of canine chemotherapy-induced vomiting and inappetence
Introduction
Chemotherapy-induced vomiting and inappetence is 
a common side effect of chemotherapeutic treatment, 
typically affecting half of receiving patients1, that can 
lower quality of life and functionality. While human 
oncology has well-established protocols for 
preventing these side effects, veterinary medicine 
does not. In fact, lymphoma accounts for 7-24% of 
all canine cancer diagnoses, but there is still no 
standardized protocol for testing and treatment.2
Even in human medicine, there is a general trend in 
under treatment of patients receiving highly emetic 
chemotherapy and over treatment of patients 
receiving low or minimally emetic chemotherapy.3
Statement of Purpose: The objective of this 
research is to establish a baseline regarding current 
standard of care to determine how veterinary 
specialists are managing vomiting and inappetence in 
dogs receiving chemotherapy. 
Methodology 
• Conducted as an online survey sent via listserv to 
approximately 1800 veterinary specialists 
• The survey inquires: 
• Whether or not the specialist accompany the 
most commonly used chemotherapy treatments 
with prophylactic antiemetic therapy to prevent 
canine vomiting on Day 1 (acute) and Days 2-5 
(delayed).
• To estimate the likelihood of vomiting expected 
during the given time periods. 
• To depict what types of antiemetic therapies are 
used in prophylactic or reactive treatment of 
vomiting.
• To indicate the most common appetite 
stimulants they use in treating inappetence in 
canines receiving chemotherapy. 
Conclusions/Future Directions
• Data obtained in this survey will help contribute 
to the development of antiemetic and inappetence
prevention and treatment guidelines in dogs 
receiving chemotherapy.
• Future clinical trials will assess the management 
of vomiting and inappetence in dogs with 
lymphoma being treated with chemotherapy and 
compare oncologists’ perceptions with evaluations 
made by dog owners.
Results
• The survey was sent out Vomiting (Prophylactic and Reactive
April 2, 2016. Treatment, Products) for Day 1 and 
• The results are statistics only, Days 2-5:
no statistics performed. 1. Maropitant (NK1 antagonist)
• Demographics: 2. Ondansetron (5-HT3 antagonist)
• 145 responses (140 DVM, 5 Nurses) 3. Metoclopramide (D2 antagonist)
• 98 (68%) boarded oncologists
• 98 (68%) with medical oncology Inappetence (Treatment, Products)
being >60% of their daily practice 1. Maropitant (NK1 antagonist)
• 101 (70%) private practice; 43 (30%) 2. Mirtazapine (NaSSA antidepressant)
academic 3. Metoclopramide (D2 antagonist)
Vomiting (Prophylactic Treatment, 
Yes/No); Day 1 (>50%):
Vomiting (Prophylactic Treatment, 
Yes/No); Day 2 (>50%):
Cisplatin, Streptozocin, Dacarbazine, 
Paclitaxel, Epirubicin, Doxorubicin
Cisplatin, Dacarbazine, Doxorubicin, 
Paclitaxel, Streptozocin
Vomiting (Likely to cause > Grade 2 
adverse event); Day 1 (Most 
emetogenic, responses indicating 
>50% likelihood):
Vomiting (Likely to cause > Grade 2 
adverse event); Days 2-5 (Most 
emetogenic, responses indicating 
>50% likelihood): 
Cisplatin, Streptozocin, Dacarbazine, 
Paclitaxel, Epirubicin, Doxorubicin, 
Mechlorethamine
Cisplatin, Streptozocin, Paclitaxel, 
Dacarbazine, Epirubicin, Doxorubicin, 
Mechlorethamine
Discussion
• Chemotherapies likely to be most emetogenic
clinically: 
• Cisplatin, Streptozocin, Dacarbazine, Paclitaxel, 
Epirubicin, Doxorubicin, Mechlorethamine
• Chemotherapies considered most likely to cause 
acute emesis (Day 1) and delayed emesis (Days 2-
5) are very similar.
• Most common antiemetic therapy in both the 
acute (Day 1) and delayed (Days 2-5) setting 
AND preventative and reactive (after vomiting 
has occurred) setting: 
• Maropitant, Ondansetron, Metoclopramide
• Chemotherapies most likely to cause inappetence
are the same as those most likely to cause emesis.
• Clinical studies have documented the percent of 
treated canines showing decreased appetite:
• Carboplatin 25% (7/28) in cats and dogs*4
• Vincristine 43% (25/57)5
• Cyclophosphamide 36% (15/42)5
• Toceranib phosphate 39% (34/87)6
• Doxorubicin 33-53% (n=49)*7
• Maropitant, an antiemetic therapy, is the most 
commonly utilized therapy for appetite 
stimulation. 
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Inappetence (Likely to cause > Grade 
2 adverse event); Day 1 (Most likely 
to cause inappetence, responses 
indicating >50% likelihood)
Inappetence (Likely to cause > Grade 
2 adverse event); Days 2-5 (Most 
likely to cause inappetence, responses 
indicating >50% likelihood) 
Cisplatin, Streptozocin, Paclitaxel, 





Preliminary data: results still being accrued.
